Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 diseases that affect the lung interstitium. These conditions, characterized by varying degrees of inflammation and fibrosis, present a diagnostic and therapeutic challenge for healthcare professionals due to their complex etiology and clinical presentation.
ILDs can be classified into idiopathic and secondary forms. The idiopathic forms, including idiopathic pulmonary fibrosis (IPF), are of unknown cause. Secondary ILDs can occur due to systemic diseases, occupational exposure, drugs, and radiation. Understanding the cause is crucial, as it greatly influences the management and prognosis of the disease.
Patients with ILDs often present with non-specific symptoms such as dyspnea and cough. The diagnosis of ILDs involves a comprehensive assessment including clinical evaluation, radiological imaging, and sometimes, lung biopsy. High-resolution computed tomography (HRCT) is the gold standard imaging technique for ILDs, providing detailed information about the lung architecture.
The management of ILDs is complex and depends on the underlying cause. For IPF, antifibrotic drugs such as pirfenidone and nintedanib have shown to slow disease progression. In secondary ILDs, treating the underlying cause is paramount. Lung transplantation may be an option for selected patients with advanced disease. The prognosis of ILDs varies widely, with IPF having the worst survival rates.
Interstitial lung diseases are a diverse group of disorders with a complex etiology and clinical presentation. Accurate diagnosis and appropriate management are key to improving patient outcomes. As healthcare professionals, staying updated on the latest advancements in the field is vital to provide optimal care to patients with these challenging conditions.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation